The economic evaluation of an antibiotic checklist as antimicrobial stewardship intervention

J Antimicrob Chemother. 2017 Nov 1;72(11):3213-3221. doi: 10.1093/jac/dkx259.

Abstract

Objectives: An antibiotic checklist was introduced in nine Dutch hospitals to improve appropriate antibiotic use. We estimated the cost-effectiveness of checklist use.

Methods: We compared 853 patients treated with an antibiotic before checklist introduction (usual care group) with 1207 patients treated after introduction (checklist group). We calculated the change of costs between these groups per unit effect [incremental cost-effectiveness ratio (ICER)]: per extra patient receiving appropriate treatment; and per day reduction in length of hospital stay (LOS). We also calculated the benefit-to-cost ratio per day reduction in LOS. Finally, we estimated the number of checklists after which the expected benefits would compensate for costs in one hospital.

Results: The cost of checklist use per patient was €10.10. Of the usual care patients, 48.8% received appropriate antibiotic treatment compared with 67.5% of the checklist patients (+18.7%). The ICER was €54.01 (1010/18.7) per extra patient with appropriate treatment. In a model calculation the expected effect of appropriate antibiotic use was a reduction in LOS of 1.05 days, which was extrapolated to a reduction of 19.64 hospital days per 100 patients. The ICER was €51.43 (1010/19.64) per day reduction in LOS. The estimated benefit of a 1 day reduction was €611. The benefit-to-cost ratio was 11.9 (611/51.43) per day reduction in LOS, indicating a cost saving of €12 for every euro spent on checklist use. The benefits would compensate for costs after use of 11 checklists.

Conclusions: Efforts for further implementation of the antibiotic checklist can be justified by potential economic benefits.

MeSH terms

  • Anti-Bacterial Agents / economics*
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Stewardship* / economics
  • Antimicrobial Stewardship* / methods
  • Checklist / economics*
  • Cost-Benefit Analysis
  • Female
  • Hospitals / statistics & numerical data
  • Humans
  • Length of Stay / economics
  • Male
  • Middle Aged

Substances

  • Anti-Bacterial Agents